Salt sensitivity of blood pressure is a cardiovascular risk factor, independent of and in addition to hypertension. In essential hypertension, a conglomerate of clinical and biochemical characteristics defines a salt-sensitive phenotype. Despite extensive research on multiple natriuretic and antinatriuretic systems, there is no definitive answer yet about the major causes of salt-sensitivity, probably reflecting the complexity of saltbalance regulation. The endothelins, ubiquitous peptides first described as potent vasoconstrictors, also have vasodilator, natriuretic and antinatriuretic actions,
Introduction
It has long been known that blood pressure (BP) responses to salt-loading and unloading are heterogeneous and exhibit a Gaussian distribution in both normotensive and hypertensive human beings. It took several decades to produce the evidence that salt-sensitivity and salt-resistance of BP are phenotypes, rather than a reflection of random variability of BP responses to salt. Hence, these responses are reproducible over time, 1 reproducible when measured with different protocols, 2 and closely associated in mono and dizygotic twins. 3 Different methods have been employed to study salt-sensitivity of BP in humans, including rapid intravenous salt loading and pharmacologic (furosemide) salt depletion, 4 and prolonged dietary salt manipulation. 2 The magnitude of BP responses employed as a cut-off for definition of salt-sensitivity vs salt-resistance has been set at different arbitrary levels by different laboratories. 4, 5 Despite these methodological issues, there has been remarkable agreement on several clinical and biochemical characteristics that are common in saltsensitive hypertensive humans. They include high prevalence in African Americans, 4, 6, 7 increasing prevalence with aging, 1, 8 low PRA with blunted responses to its physiological stimuli 2 or normal PRA in so-called 'non-modulators' of renal blood flow, 9 a suppressed kallikrein-kinin system 10, 11 and excess activation of the arginine-vasopressin pressor system. 12 Associations with gender, 4,13 a hyperactive sympathetic system, 4,14 a hypoactive dopaminergic system, 15 obesity and insulin resistance are controversial, which may be explained if salt-sensitivity of BP is not a pure phenotype. This is supported by the finding of opposite alterations of insulin sensitivity in the low-renin vs non-modulating groups of salt-sensitive hypertensive patients. 16 Perhaps the most relevant findings emerging from the studies of salt-sensitivity of BP are the prognostic ones. There is evidence that salt-sensitive hypertensive patients exhibit excess prevalence or severity of left ventricular diastolic dysfunction 17 and hypertrophy 18 (perhaps linked to decreased nocturnal 'dipping' of BP 19 ) and increased incidence of stroke 20 and severity of microalbuminuria. 21 This end-organ damage pattern resembles that of saltsensitive hypertensive rats, such as DOC-salt and Dahl-salt-sensitive (SS). Most recently, Weinberger and co-workers have provided evidence that salt-sensitivity of BP of normotensive individuals carries with it the same detrimental long-term prognosis (mortality) as hypertension in salt-resistant patients. 22 This emphasises the need for continued research on the cause(s) of salt-sensitivity or on its intermediate mechanisms, particularly if the results of these studies can be exploited for the tailoring and targeting of specific therapy to salt-sensitive patients.
Complexity of the search for cause(s) of salt-sensitivity of BP
The identification of the gene or genes involved in determining salt-sensitivity of BP would be facilitated by a precise characterisation of the salt-sensitive intermediate phenotype. There have been innumerable studies of alterations in pressor/ depressor and natriuretic/antinatriuretic systems in salt-sensitive animals and humans, attempting to refine the definition of this phenotype, and some candidate genes have been proposed by linkage and association studies (see review by Luft 23 ). However, the search remains somewhat elusive, which is most likely accounted for by the complexity of the factors and interactions that regulate salt balance. Figure 1 (left panel) provides a scheme, derived from the classical studies of Guyton and coworkers, indicating that the intact animal, as opposed to an isolated kidney, is salt-resistant because during a salt load, several pressor-antinatriuretic systems are inhibited, while several depressor-natriuretic systems are concomitantly stimulated. This permits excretion of the salt-load without the need to resort to pressure natriuresis. Figure 1 Schematic representation of the mechanisms through which salt-sensitivity of BP is established. On the left, there is no change in BP from a low to a high salt intake because there is concomitant stimulation of depressor-natriuretic and inhibition of pressor-antinatriuretic systems. Thus, the sodium load is excreted without the need for pressure natriuresis. In contrast, one or several of these salt-regulating mechanisms have been clamped in the right panel, at the level that is physiologic for a low salt intake. In the absence of these regulatory mechanisms, BP increases in response to a salt-load, to participate in the restoration of salt balance via pressure-natriuresis.
All research on mechanisms of salt-sensitivity of BP in humans or animals can be conceptualised, within this framework, as experiments in which either nature or the investigator has 'clamped' one of these systems, avoiding its normal regulation by salt intake and therefore producing salt-sensitivity of BP (ie, a 'shift' in the pressure natriuresis curve, Figure 1, right panel) .
'Clamping' of pressor-antinatriuretic systems at a stimulated level that is only appropriate for a lowsalt intake can be produced by: (a) exogenous administration (eg, experimental angiotensin IIinfusion and DOC-salt hypertension in the rat); (b) inbreeding of a biochemical abnormality (eg, increased vasopressin levels 24 or endogenous inhibitors of nitric oxide synthase 25 in Dahl SS rats; overproduction of vasoconstrictor 20-HETE 26, 27 or impaired downregulation of sodium retaining insulin receptors 28 in spontaneous hypertensive rat (SHR) kidney; and mutations in adducin with increased Na + /K + pump activity in Milan rats 29 ); or (c) spontaneous gene polymorphisms in humans (eg, shorter intronic repeats of the 11-HSD2 gene with decreased activity of the enzyme and increased cortisol-induced mineralocorticoid effect, 30 and mutations in the G-protein ␤3 subunit with increased activity of the salt-retaining antiporter transport system 31 ). Analogously, depressor-natriuretic systems may be 'clamped' at their suppressed level only appropriate for a low-salt intake, thus leading to salt-sensitivity of BP when the animal or subject is given a salt-load. Examples include: (a) exogenous inhibition of the natriuretic sensory nervous system, 32 nitric oxide, [33] [34] [35] or natriuretic eicosanoids; 36 (b) knockout of the proANP gene in mice; 37 (c) inbreeding of biochemical abnormalities such as deficient renal medullary natriuretic 20-HETE 38 or nitric oxide 33, 34, 39 in Dahl SS rats; and (d) blunting of ANP, 40 nitric oxide, 41 kallikrein, 10, 11 dopaminergic, 15 and ␤2 adrenergic 42 systems as described in salt-sensitive hypertensive humans.
Thus, alterations in any of the multiple mechanisms that regulate salt balance may lead to saltinduced hypertension. This multiplicity, compounded by the interactions between these regulatory systems, has produced lack of definitive answers regarding the major causes of salt-sensitivity of BP.
Kidney transplantation experiments and salt-sensitivity of BP
Experiments conducted soon after the development of the Dahl strains of salt-sensitive (SS) and saltresistant rats (SR), provided an important clue for research on the mechanisms of salt-sensitivity of BP, ie, that the recipient animal acquires the BP of the kidney donor. 43 This is even observed when the kidneys of young (8-9 weeks old) Dahl SR are transplanted into salt-fed, adult Dahl SS rats, with normalisation of the established hypertension of the latter. 44 Analogous experiments were conducted in the Milan strain of salt-sensitive rats with similar results. 45 The initial interpretation of these experiments was that the transplanted abnormality had to be one affecting renal sodium handling. However, when Dahl SS and Dahl SR rats are subject to marked increase in salt intake over 96 hours, their body weight, plasma volume and cardiac output do not differ significantly, despite a substantial increase of BP in Dahl SS only. 46 These findings may be interpreted as an abnormal adaptation of total peripheral resistance to volume expansion in salt-sensitive rats, as if their kidneys produced a vasoconstrictor humoral factor. These transplantation experiments and haemodynamic measurements suggest that the search for the major causes determining salt-sensitivity of BP should be focused on renal factors. Candidate mechanisms or substances should be those capable of producing renal or systemic vasoconstriction, subtle changes in natriuresis with shift in the pressure-natriuresis curve, or a combination of both.
Endothelins and BP regulation
The three 21-aminoacid endothelin peptides are potent vasoconstrictors. Although their name derives from their original discovery in the endothelium, they are now known to be ubiquitous. Endothelial endothelin, or ET-1 acts on two receptors, ET A and ET B , located in adjacent endothelium and vascular smooth muscle. The vasoconstrictor, proliferative and hypertrophic actions of ET-1 on vascular smooth muscle are exerted via both these receptors. 47 In contrast, endothelial ET B stimulation acts as an opposing vasodilator, by enhancing the synthesis of relaxing compounds, such as nitric oxide and prostaglandins. 48 In the kidney, locally generated endothelin produces ET A -mediated vasoconstriction and antinatriuresis 49 but also very important ET B -mediated diuresis and natriuresis via inhibition of vasopressin-induced synthesis of cyclic AMP, 50 and of the activity of tubular Na
Endothelins were discovered and described predominantly as pressor agents. Whether this is true in the normal animal has recently become more controversial. For example, mice heterozygous for the knockout of the ET-1 gene were unexpectedly found to be hypertensive, not hypotensive. 52 This paradox was initially interpreted as an endothelin-independent, sympathetic-driven phenomenon, due to concomitant ventilatory abnormalities in these animals. However, mice engineered for diminished expression of the ET B receptor gene (which have neither the ventilatory abnormalities of the ET-1 knockout, nor the colonic abnormalities of the ET B receptor knockout) also develop hypertension. 53 Therefore, the seemingly counterintuitive view that in normal animals the endothelin system may be predominantly vasodilator has been recently strengthened. There are no direct studies to estabJournal of Human Hypertension lish whether disruption of the ET B gene contributes to hypertension via impaired natriuresis also. However, ET B receptor knockout mice are salt-sensitive, and this abnormality does not reverse with ET A blockers, 54 suggesting an antinatriuretic mechanism in their hypertension.
Despite the findings above, there is definite evidence that the pressor action of excess ET A vasoconstriction plays a role in several models of experimental hypertension in the rat (see below). The predominant vasoconstrictor role of endothelin in these experiments, as opposed to a possible predominant vasodilator-natriuretic role in normal animals, may be accounted for by overexpression of vascular endothelin in certain forms of experimental hypertension. 55, 56 In normal human volunteers, most, 57, 58 but not all 59 investigators have documented that there is tonic ET A -vasoconstriction, while all agree on the existence of ET B -vasodilation in the control of regional blood flow. 57, 58 Analogous observations have been made for the control of total peripheral resistance, which is diminished by ET A and increased by ET B blockers. [60] [61] [62] The relative quantitative contribution of these two components to the regulation of normal BP has not been established. In essential hypertension, vasoconstriction of regional (forearm) vascular beds by ET A seems to be enhanced, 58, 59 and dilation by ET B abolished or reversed. 59 These changes may be due to increased ET-1 in resistance vessels of hypertension, 63, 64 the synthesis of which is shifted from the endothelium to the vascular smooth muscle cells of the tunica media. 64 Bosentan (a combined ET A /ET B receptor blocker) exerted significant antihypertensive action in a large double-blind clinical trial, 65 indicating that the pressor component of the endothelin system is tonically present in human hypertension. However, the magnitude of BP reduction by bosentan in this trial was barely greater than that observed in normotensive humans. This could be interpreted as a lack of specific, exaggerated contribution of endothelin to the vasoconstriction of essential hypertension. Alternatively, a larger antihypertensive effect in a subset of patients may have been masked or diluted by recruitment of an unselected hypertensive population, since an endothelin-dependent subset of essential hypertensive patients has not yet been well characterised.
In summary, due to the multiplicity of their actions, the endothelins are obvious candidate substances for a causative or intermediate role in saltsensitive hypertension. This could be related to excessive ET A vasoconstriction or antinatriuresis, to defective ET B vasodilation or natriuresis, or to a combination of any of these four mechanisms.
Endothelin and experimental saltsensitive hypertension
Early research on the participation of endothelin in models of experimental hypertension in the rat made it clear that overexpression of endothelial endothelin and participation of this peptide in development and maintenance of hypertension and vascular remodelling were much more important in DOC-salt rats than in SHR. 55, 66, 67 These observations were extended by other laboratories and it can now be concluded that endothelin plays more of a vasoconstrictor and hypertrophy-promoting role in saltdependent (eg, DOC-salt, aldosterone-induced, Dahl SS, insulin-resistant, and 1K-1C Goldblatt models), 55, 66, [68] [69] [70] than in salt-independent or renindependent forms of experimental hypertension (eg, SHR, 2K-1C Goldblatt, and L-NAME-induced hypertension). 55, 56, 67, 70 The only exception seems to be the hypertension produced by exogenous administration of angiotensin II, in which endothelin participates in BP maintenance and vascular hypertrophy. 71 Continuous stimulation of endothelin production by exogenous angiotensin infusion 72 may outweigh the complex interactions between intermittent activation of the endogenous reninangiotensin and endothelin systems, and thus explain this exception.
Endothelin and hypertension in humans
With the advent of sensitive and specific radioimmunoassays, increased plasma levels of immunoreactive endothelin were reported in several forms of secondary hypertension in humans, including cyclosporine-induced hypertension in transplant patients, 73 erythropoietin-induced hypertension in dialysis patients 74 and sleep apnea-induced hypertension. 75 In pre-eclampsia, concomitant increase of plasma endothelin and endothelial elastase supports participation of endothelial dysfunction in the hypertension. 76 Patients with chronic renal failure have increased local renal production of endothelin, which correlates negatively with glomerular filtration rate. 77 In addition, their elevated endothelin plasma levels 78 exert an unequivocal pressor action, as demonstrated by the antihypertensive effect of an ET A /ET B receptor blocker in patients with renal disease. 54 Analogously, in patients with endothelinsecreting malignant haemoangioendotheliomas, removal of the tumour led to resolution of the hypertension. 79 Reports on plasma endothelin in essential hypertension have been controversial, with increased levels published by some, 80, 81 but not all investigators. 82, 83 It has now become evident that two reasons account for this apparent controversy. First, plasma endothelin tends to be elevated when hypertension is severe, with concomitant end organ damage. We have confirmed, in 47 essential hypertensive patients, that strong correlations between mean ambulatory BPs and plasma endothelin were due to a few individuals with very high BPs and endothelin levels, while the relationship between these parameters was much more scattered in the mid-range for their respective values. 84 The second reason is that plasma endothelin tends to be higher in hypertensive patients with certain clinical and biochemical characteristics, including African-American race, 85 low PRA, 86 obesity, 87 and insulin resistance. 88 Because these characteristics are also clinical and biochemical correlates of the salt-sensitive hypertension phenotype, it is not surprising that plasma endothelin was found to be elevated in hypertensive patients classified as salt-sensitive with a chronic dietary protocol. 89 Consistent with this, we found that racial differences in endothelin levels are not present when equal proportions of salt-sensitive and salt-resistant African American and Caucasian individuals are included in the study. 84 Participation of endothelin in salt-sensitive essential hypertension could be mediated by a deficit in its natriuretic actions, or by an exaggerated contribution to the control of vasoconstriction, particularly during changes in salt balance. We will review the evidence for these mechanisms in human salt-sensitive hypertension.
Urine endothelin, salt-balance and saltsensitive hypertension in humans
Filtered circulating endothelin is degraded by neutral endopeptidase. 90 Only negligible amounts of radiolabelled endothelin are recovered in the urine after injection in the systemic circulation. 91 Therefore, urine endothelin predominantly reflects production of local, renal endothelin. Fractional excretion of endothelin is about 1.0 in normal human beings, 77, 92 indicating that renal production of this peptide is of a magnitude similar to that of its filtered load.
Several lines of evidence support a major role for tubular endothelin in the regulation of salt excretion in normal and hypertensive subjects. Hence, the excretory circadian rhythms for endothelin and sodium exhibit a parallel pattern, 93 there are positive correlations between natriuresis and urine endothelin, 93, 94 between fractional excretion of sodium and that of endothelin, 92 and between changes in natriuresis and urine endothelin produced by a salt load. 95 Interrelationships between the urine excretion of sodium, the natriuretic peptide adrenomedullin, and endothelin, 95 and increased urine excretion of endothelin after a salt load [92] [93] [94] [95] also support participation of this peptide in regulation of salt balance, although the latter observation has not been confirmed by all laboratories. 96, 97 The basal urine excretion rate of endothelin is diminished in hypertension, more so in salt-sensitive patients, and there is a negative correlation between urine endothelin and mean arterial pressure (MAP) in normotensive and hypertensive subjects. 96 These observations are consistent with a role for endothelin in salt-sensitivity of BP via diminished natriuresis. An analogous mechanism has been proposed in SHR, since this strain exhibits impairment of renomedullary synthesis of endothelin. 98, 99 Inability to confirm decreased absolute levels of endothelin excretion in hypertensive patients by other authors 93, 97 may reflect differences in endothelin plasma levels and renal function of the studied subjects. When these parameters are taken into consideration, it is unequivocal that fractional excretion of endothelin is reduced almost three-fold in essential hypertensive patients compared to normotensive controls. 77 Finally, in response to a salt load, hypertensive patients with delayed natriuresis have less of an increase in urine endothelin compared to those with the characteristic exaggerated natriuresis of hypertension. 93 Therefore, reduced basal urine endothelin and blunted renal endothelin responsiveness to a salt load most likely participate in the pathogenesis of human salt-sensitive hypertension.
Plasma endothelin, salt-balance and saltsensitive hypertension in humans
In contrast to the relatively well characterised provenance of urine endothelin, the origin of circulating, plasma endothelin is less well known. Conceivably, a large part of it is of endothelial origin, reflecting very minimal spillover from the predominant abluminal (ie, toward the smooth muscle layer) secretion of endothelin by endothelial cells. 100 Release of organ-specific endothelin to the circulation, such as that from the neurohypophysis 101 is another possible source. Studies on the regulation of plasma levels of endothelin of hypertensive subjects by salt balance have provided diverse results. When patients are not characterised beyond a diagnosis of essential hypertension, sodium loading or unloading does not seem to have a significant effect on plasma levels of the peptide, 92, 95, 96, 102 an observation that we have confirmed in our patients. 84 Classifying patients into salt-sensitive and saltresistant, Ferri et al reported 42-44% higher levels of plasma endothelin in the former group, 2 weeks after a 120 mmol NaCl diet. 89, 97 Although statistically significant, these changes occurred near the lower limit of detection of the peptide, with values ranging between 0.65 and 1.30 pg/ml. Also, the population of these studies was highly selected (with exclusion of females, severe hypertension, obesity, smoking, diabetes, and atherosclerosis), and experienced large attrition due to problems complying with the diets. It is therefore unclear whether these findings can be extrapolated to all salt-sensitive hypertensive humans. Nonetheless, the authors speculated that increased plasma endothelin may be a marker of more severe endothelial dysfunction in salt-sensitive patients than in their salt-resistant counterparts (correlations between endothelin, von Willebrand factor and endothelial selectin 89 ) and also that it may be involved in the causation of endothelial damage, particularly in the kidney (correlations between plasma endothelin and urine microalbumin in salt-sensitive patients only 97 ). In contrast to these observations, the group of Bragulat et al did not detect differences in plasma endothelin between salt-sensitive and salt-resistant hypertensive patients, after 1 week of low (50 mmol) and 1 week of high (250 mmol) salt intake. 102 It is noteworthy that this observation was made in patients who had unequivocal endothelial dysfunction, as assessed by forearm blood flow responses to acetylcholine and urine excretion of nitrates. Consistent with this observation, we did not detect differences in plasma endothelin of salt-sensitive and salt-resistant patients when the measurements were carried out before initiation of an acute protocol of salt loading and unloading, that is, while they still were on their habitual salt intake. 84 The differential effects of salt loading and salt deprivation on plasma endothelin of salt-sensitive and salt-resistant patients also vary, probably depending on the patient population and the experimental protocol employed. Thus, Ferri et al 89 reported increases in plasma endothelin from a low (20 mmol) to a high salt diet (220 mmol) given for 14 days. Although the increase was observed in both salt-sensitive and salt-resistant patients, the magnitude was greater in the former (46%) than in the latter (22%). In contrast, the patients of Bragulat et al 102 exhibited a slight (not significant) decrease of plasma endothelin when switching from one week of 50 mmol NaCl intake to another week on 250 mmol. There was no difference in the magnitude of this decrease between salt-sensitive (7%) and salt-resistant patients (9%). From these two studies, it may be speculated that a sustained high sodium intake may be required to produce and detect impairment of endothelial function specific to salt-sensitive patients.
We studied changes of plasma endothelin in response to acute manipulation of salt balance with an in-patient protocol. Salt-loading was achieved in 24 h with a 160 mmol diet plus 300 mmol given as intravenous saline over 4 h. Salt depletion was produced in the ensuing 24 h with a 10 mmol NaCl diet and three 40 mg doses of furosemide. 84 Essential hypertensive patients were classified as salt-sensitive, indeterminate or salt-resistant according to their BP response to salt-deprivation. There was no difference in plasma endothelin levels among the three groups before the protocol, ie, during their habitual salt intake, and there were no significant changes in levels of the peptide in any of the three groups due to salt-loading. In contrast, during acute salt-deprivation, salt-sensitive patients exhibited an 18% increase in plasma endothelin while salt-resistant subjects had a 10% decrease. Patients classified as indeterminate exhibited a minor change (+4%) that was not different from zero ( Figure 2) . As a consequence of these opposite changes in endothelin in response to salt-deprivation, salt-sensitive patients had significantly higher plasma levels in the salt-depleted state, compared to the other two groups. We showed that these different responses were not due to classification of patients into groups with arbitrary cut-offs, because the relationship between salt-sensitivity of BP and change in plasma endothelin due to salt deprivation was continuous throughout the patient population. Before initiation of the protocol, there was a negative relationship between plasma endothelin and PRA in all patients, as reported by others. 94 During salt-deprivation, the changes in endothelin correlated with the changes in catecholamines. In view of this combination of findings, we speculated that in the presence of a blunted renin-angiotensin system (a characteristic of salt-sensitive hypertension), salt-deprivation leads to compensatory stimulation of other pressors, including catecholamine-driven endothelin secretion. 103 In brief, baseline differences in plasma endothelin between salt-sensitive and salt-resistant patients are equivocal or at best, minor. However, salt-sensitive patients have exaggerated or abnormal increases in plasma circulating levels of the peptide in two situations, chronic sustained severe salt-loading, and rapid salt deprivation. Although the mechanism of these responses seems to be different (salt-induced or pressure-induced endothelial damage for chronic dietary loading vs compensation of a blunted reninangiotensin system during acute salt depletion), it is clear that these observations may have therapeutic implications because in both cases, increased plasma endothelin levels predict BP dependency on the peptide, thus a therapeutic response to blockers of its receptors. Confirmation of this prediction awaits further trials with the forthcoming endothelin blockers in development by industry.
Conclusion
We have reviewed the possible role for urinary (ie, renal natriuretic) and circulating (most likely endothelial) endothelin in the pathogenesis of saltsensitivity of BP. Figure 3 depicts a conceptual framework that unifies the work of the multiple laboratories discussed in the review. It is suggested that a deficit in the synthesis of renal tubular endothelin, analogous to that of the SHR strain, may be an initiating factor for salt-sensitivity of BP, via impaired natriuresis. Once salt-sensitive hypertension is established, exposure to chronic elevated salt intake may contribute to exaggerated hypertension, shear stress, endothelial damage and further release of endothelin, with spillover to the plasma and increased circulating levels. In a seemingly paradoxical way, episodic salt deprivation (be it due to the circadian rhythm of salt intake, salt-restricted diet or use of diuretics) also has the potential for increasing circulating endothelin, particularly in low-renin essential hypertensives, via stimulation by the sympathetic nervous system.
At both extremes of salt balance, increased plasma (and perhaps tissue) endothelin will therefore contribute to the vasoconstriction of salt-sensitive hypertension and to its end-organ damage. Progression of microalbuminuria and decreased glomerular filtration rate may switch the patient from this pattern peculiar to salt-sensitive hypertension to the pattern observed in chronic renal insufficiency, ie, decreased clearance of circulating endothelin with further increase in plasma levels, and increased Figure 3 Depiction of a hypothetical sequence of events by which endothelin (ET) participates in salt-sensitivity (SS) of hypertension. The primary event is a decrease in the production of renomedullary endothelin that leads to diminished natriuresis and salt-sensitive hypertension. At both extremes of salt balance, there are mechanisms that will lead to increase in plasma endothelin levels (see text). Increased circulating endothelin participates in further blood pressure (BP) elevation (vasoconstriction) and cardiovascular (CV) and renal damage (growth promoting effects and remodelling). Renal dysfunction closes the circle by increasing renal production and decreasing clearance of plasma endothelin. ET B = B-type endothelin receptor, RAS = renin-angiotensin system, GFR = glomerular filtration rate. renal production of vasoconstrictor vascular or mesangial endothelin. This would close a vicious circle of endothelin-induced end-organ damage in saltsensitive hypertension.
Proving whether decreased renal synthesis of endothelin is a primary event in salt-sensitive hypertension will have to wait for experiments of targeted, kidney-specific disruption of the expression of the ET-1, ET A or ET B genes. From the clinical standpoint, however, more important than establishing whether endothelin has a primary or secondary role, is to test the conceptual scheme above in terms of its therapeutic implications. The hypothesis predicts that endothelin-receptor blockers (perhaps more so the ET A specific) will have an enhanced therapeutic action on BP and more importantly on end-organ damage, in salt-sensitive hypertension, a contention that can easily be proven in direct fashion by appropriate clinical trials with these agents.
